A Phase I Trial to Investigate the Effect of Nintedanib on the Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Patients With Non-small Cell Lung Cancer

Trial Profile

A Phase I Trial to Investigate the Effect of Nintedanib on the Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Patients With Non-small Cell Lung Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Sep 2017

At a glance

  • Drugs Nintedanib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Pharmacokinetics
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 18 Sep 2017 Planned End Date changed from 27 Jul 2018 to 28 Sep 2018.
    • 18 Sep 2017 Planned primary completion date changed from 27 Jul 2018 to 28 Sep 2018.
    • 05 Sep 2017 Planned End Date changed from 29 Dec 2017 to 27 Jul 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top